Mircom International Content Management & Consulting Ltd & Ors v Virgin Media Ltd & Anor

Factual and Procedural Background

The Applicants seek Norwich Pharmacal relief requiring the First Defendant ("Virgin") to disclose the names and addresses of tens of thousands of residential broadband subscribers accused of unlawfully downloading explicit pornographic films. Two related claims were issued by Part 8 claim forms in February 2019: the first ("the Mircom Claim") and the second ("the GEIL Claim"). Neither Mircom nor Golden Eye, the first claimants in each respective claim, are copyright owners; the other claimants are film production companies. The orders sought would compel Virgin to disclose subscriber information in batches, enabling the Applicants to send letters alleging copyright infringement and proposing settlements. Virgin opposes the relief, submitting detailed arguments against it, asserting that the Applicants' business model revolves around obtaining such disclosures and seeking payments, and challenging the evidential basis and intentions of the Applicants. The Court must determine whether the Applicants meet the legal criteria to justify disclosure under Norwich Pharmacal principles, considering the evidential sufficiency and proportionality of the relief requested, as well as the impact of data protection laws, particularly the GDPR.

Legal Issues Presented

1. Whether the correct legal approach to Norwich Pharmacal relief claims remains that set out in the 2012 Golden Eye litigation.
2. Whether the Applicants' evidence as served justifies the order sought or whether the order should be made subject to rectification of evidential defects.
3. The impact of the Supreme Court's judgment in Rugby Football Union v Viagogo on the legal approach to such claims.
4. The implications of the GDPR and the Data Protection Act 2018 on the Applicants' status as data controllers or recipients and the proportionality of disclosure.

Arguments of the Parties

Applicants' Arguments

• The Applicants contend that the legal framework established in the 2012 Golden Eye litigation remains applicable and should be applied to the present claims.
• They argue that the evidence, while having some technical defects, supports a good arguable case of copyright infringement via IP addresses identified by their monitoring software.
• The Applicants submit that they are merely data recipients under GDPR and not data controllers, relying on statutory provisions exempting disclosure required by law or court order from certain GDPR obligations.
• They propose rectifying evidential deficiencies by submitting updated fact and expert evidence if the Court is inclined to grant relief.
• The Applicants deny that their business model is a "money-making scheme" and assert a genuine intention to vindicate intellectual property rights.

Defendant's Arguments

• Virgin challenges the sufficiency and reliability of the Applicants' fact and expert evidence, highlighting fundamental defects such as missing exhibits, outdated expert reports, and lack of proper statements of truth.
• Virgin submits that the Applicants' business model consists primarily of obtaining disclosure orders to demand settlements, without genuine intention to pursue substantive litigation.
• They argue that the impact of the GDPR requires careful consideration of data protection rights and proportionality, potentially affecting the availability of Norwich Pharmacal relief.
• Virgin disputes the applicability of the 2012 Golden Eye approach in light of subsequent legal developments, including the Viagogo judgment and data protection law changes.
• They raise concerns about the accuracy of identification of infringers, increased risks of false positives, and the evidential basis for claims involving data gathered in Germany.

Table of Precedents Cited

Precedent	Rule or Principle Cited For	Application by the Court
Golden Eye (International) Ltd v Telefónica UK Ltd [2012] EWHC 723 (Ch); [2012] RPC 28; [2012] EWCA Civ 1740	Sets out the legal framework and conditions for granting Norwich Pharmacal relief in copyright infringement cases involving IP address disclosures; establishes the requirement of a good arguable case and proportionality balancing.	The Court confirmed that the 2012 Golden Eye approach remains the correct legal framework and applied its principles in assessing the present claims, including the balancing exercise concerning privacy and proportionality.
Rugby Football Union v Viagogo [2012] UKSC 55	Consideration of the applicant's motive and the correct legal approach to Norwich Pharmacal relief; approved relevant legal tests in Golden Eye.	The Court rejected the argument that Viagogo changed the legal approach established in Golden Eye, noting that the Supreme Court approved Golden Eye’s principles.
AB Bank v Abu Dhabi Commercial Bank PJSC [2017] 1 WLR 810	Clarifies that Norwich Pharmacal applications are for final relief, not interim remedies.	The Court acknowledged this procedural point but found it did not materially affect the substantive decision.
Breyer v Federal Republic of Germany Case C-582/14, EU:C:2016:779; [2017] 1 WLR 1569	Interprets whether dynamic IP addresses constitute personal data under data protection law, considering means reasonably likely to be used to identify a data subject.	The Court considered the decision but distinguished it on factual grounds, noting differences in legal systems and concluding that IP addresses in the Applicants’ hands would become personal data upon disclosure.
Ramilos v Buyanovsky [2016] EWHC 3175 (Comm)	Confirms the test of "good arguable case" for Norwich Pharmacal relief.	The Court applied the "good arguable case" standard in assessing the Applicants' evidence.

Court's Reasoning and Analysis

The Court began by confirming that the legal approach to Norwich Pharmacal relief in this context remains as set out in the 2012 Golden Eye litigation, which requires a good arguable case of infringement and a proportionality assessment balancing privacy rights against the need for disclosure. The Court rejected the submission that the Viagogo judgment altered this approach, noting that the Supreme Court had expressly approved the Golden Eye principles.

Regarding data protection under the GDPR, the Court analyzed whether the IP addresses constitute personal data and whether the Applicants would be data controllers or merely data recipients. It concluded that the IP addresses would be personal data upon disclosure, but the Applicants would be data recipients, not controllers, and thus not subject to the full range of GDPR obligations. The Court accepted statutory provisions disapplying certain GDPR requirements in the context of legal proceedings.

The Court then examined the evidential basis for the claims. It found fundamental defects in the Applicants' fact evidence, including missing critical exhibits and lack of explanation for key documents. The expert evidence was also found deficient, with outdated reports, absence of proper statements of truth, and unclear instructions. These defects were deemed sufficiently serious to warrant dismissal of the applications in their current form.

The Court considered Virgin's argument that the Applicants lacked a genuine intention to pursue infringement claims and found that the Applicants had not provided sufficient evidence about how they had used information obtained under previous court orders. This absence of evidence further undermined the Applicants’ position.

The Court declined to specify in detail what additional information would be required to satisfy the genuine intention test, preferring to address this in future applications where it is more pertinent.

Finally, the Court noted that the Applicants had proposed to rectify evidential defects by submitting updated fact and expert evidence, but as no such evidence had yet been presented, relief could not be granted at this stage.

Holding and Implications

The Court DISMISSED the applications for Norwich Pharmacal relief as currently presented due to fundamental evidential deficiencies and insufficient demonstration of genuine intention to pursue infringement claims.

The dismissal is without prejudice to the Applicants’ ability to serve corrected and updated evidence addressing the identified defects. The Court granted permission for the Applicants to apply for variation of the order conditions accordingly.

No new legal precedent was established; the decision reaffirms the applicability of the Golden Eye framework and clarifies the interaction with GDPR in this context. The ruling emphasizes the necessity for applicants seeking Norwich Pharmacal relief to present cogent, up-to-date evidence and to demonstrate genuine intention to pursue substantive claims.